Safety of intravenous immunoglobulin with regard to hepatitis C virus.
Yu
M W
MW
Laboratory of Plasma Derivatives, US Food and Drug Administration, Bethesda, Maryland, USA.
Mason
B L
BL
Guo
Z P
ZP
Tankersley
D L
DL
D006526:Hepatitis C / Q000209:etiology* / Q000821:virology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D014481:United States
D016756:Immunoglobulins, Intravenous